Active-ingredient Dossier

Enoxaparin Sodium

Active-ingredient Dossier for Enoxaparin Sodium (low molecular weight heparin). Australian brands, products, PBS listings, PBAC outcomes — compiled by…

Brand: CLEXANE
Brand: EXARANE
Brand: ENOXAJECT
Brand: ENOXAPO
Therapeutic area: Haematology
Therapeutic area: Cardiology

What is

Enoxaparin Sodium Enoxaparin Sodium is a low molecular weight heparin.

Australian brands containing

Enoxaparin Sodium — CLEXANE — EXARANE — ENOXAJECT — ENOXAPO

Therapeutic areas

Enoxaparin Sodium is registered in two therapeutic areas: cardiology (3 brands) and haematology (1 brand).

Sponsor landscape

Four sponsors market enoxaparin sodium in Australia: Sanofi-Aventis, Pharmacor, Arrotex Pharmaceuticals, and Juno Pharmaceuticals.

PBS and regulatory activity

Two brands containing enoxaparin sodium have PBS-listed items. The latest PBS schedule date is 1 May 2026. In the 2016–17 fiscal year, government expenditure on enoxaparin sodium was approximately $38.1 million across 416,756 scripts. The latest PBAC outcome was recorded on 1 July 2025, and the latest AusPAR on 31 January 2025. Three brands have PBAC outcomes on record and two brands have AusPARs on record.